Thus, our data suggest that blocking EZH2 by EPZ6438, but not GSK126 suppresses CRC procession partially through decreasing M2-type macrophage proportion and increasing the M1 type in the TME, providing more evidence for EZH2 inhibitor use in CRC treatment. This evidence concerns the gene EZH2 and colorectal carcinoma.